Peter Marks, MD, PhD, on Bringing More Gene Therapies to Patients

Video

The director of the Center for Biologics Evaluation and Research at the FDA discussed his keynote speech at the 2023 MDA Conference.

“My keynote address really focused on how we can make gene therapy for rare disorders into a reality. And that means trying to address some key things that can get in the way of getting gene therapies to patients. One of them is that manufacturing of these products is still quite expensive and complicated. And we need to try to address that.”

Peter Marks, MD, PhD, the director of the Center for Biologics Evaluation and Research at the FDA, gave the keynote address at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 19-22, in Dallas, Texas. He focused on key issues that need to be addressed in order to bring more gene therapies to patients, including manufacturing, clinical trial, commercial viability, and regulatory convergence.

CGTLive spoke with Marks about his keynote address. He discussed the current state of gene therapies, possible future directions of research, and challenges that remain to be addressed. He also touched on data presented at the conference, including positive long-term follow-up data on the gene therapy onasemnogene abeparvovec (Zolgensma; Novartis) for children with spinal muscular atrophy.

Read more coverage of the 2023 MDA Conference here.

REFERENCE
Marks P. Keynote address. Presented at: 2023 MDA Conference, March 19-22; Dallas, Texas.
Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.